This research isolates and characterizes new flavonoids from Colona leonei with promising anti-cancer properties. These compounds selectively target cancer cells while sparing healthy ones. Upcoming tests will assess their effectiveness on cancer cell lines. The work also highlights preventive benefits of flavonoid-rich foods and frames cancer as a global, personal, and societal challenge.

This research targets the earliest stage of allergic and asthmatic immune reactions by blocking key cytokine “messages” sent from T cells to B cells. Using drug-discovery techniques, the project identifies compounds that prevent immune overreaction before symptoms begin, aiming to develop a new class of long-lasting preventative allergy and asthma treatments.

The talk explains how drug discovery struggles with the enormous size of chemical space, where only a few molecules become effective medicines. Using miniaturized chemical libraries and off-rate screening, the researcher accelerates structure–activity relationships (SAR) mapping without purification. This approach has already produced promising breast-cancer drug candidates and could dramatically reduce drug-development costs.

SVAS (Supravalvular Aortic Stenosis) is a rare condition where the aorta loses elasticity, causing dangerous thickening and narrowing. Using stem-cell technology, the researcher converts skin cells into aortic smooth muscle cells to study the disease and test treatments. A promising compound restores elasticity-related structures, offering hope for future therapies and broader disease modelling.

This research searches for new antibiotics in deep-sea sponge bacteria that have evolved for 580 million years to defend their hosts. By growing these never-before-seen microbes and testing them against superbugs like MRSA, the project aims to discover urgently needed antibiotics to combat rising antimicrobial resistance.